 | |
| Clinical data | |
|---|---|
| Other names | LY-451395 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H30N2O4S2 |
| Molar mass | 438.60 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mibampator (developmental code nameLY-451395) is apositive allosteric modulator (PAM) of theAMPA receptor (AMPAR), anionotropic glutamate receptor, which was under development byEli Lilly for the treatment ofagitation/aggression inAlzheimer's disease but was never marketed.[1][2] It reachedphase IIclinical trials prior to the discontinuation of its development.[1]
Mibampator belongs to thebiarylpropylsulfonamide group of AMPAR PAMs, which also includesLY-404187,LY-503430, andPF-04958242 among others.[3] It is a "high-impact" AMPAR potentiator, unlike "low-impact" AMPAR potentiators from other classes likeCX-516 and itscongenerfarampator (CX-691, ORG-24448), and is able to elicit comparatively more robust increases in AMPAR signaling.[2] In animals, high-impact AMPAR potentiators enhancecognition andmemory at low doses, but producemotor coordinationdisruptions,convulsions, andneurotoxicity at higher doses.[4]
Mibampator failed to produce cognitive improvement in patients with Alzheimer's disease, though it did show improvements in neuropsychiatric measures.[5] A caveat of the study was that the maximally tolerated dosage of the drug could not be used due totoxicity, and dosages in the same range in rodents notably failed to improve memory-related behavior.[6]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
